Delivery Order SPE2DB25D3022-SPE2DB25FWCKX
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,037.40 to AmerisourceBergen Drug Corp for Emgality 120 mg/mL pens on July 30, 2025, with completion scheduled for July 31, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation. The contract is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania, where AmerisourceBergen operates as a major pharmaceutical distributor and critical vendor for...
- The Defense Logistics Agency awarded a delivery order valued at $1,729.00 to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen, a migraine treatment medication. This competitively awarded, firm fixed-price delivery order was issued on August 8, 2025, with an ultimate completion date of August 11, 2025. The contract utilizes no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $1,213.80 to AmerisourceBergen Drug Corp for Emgality 120 mg/mL pen injectors, with an ultimate completion date of July 29, 2025. The contract, issued on July 28, 2025, employs firm fixed-price pricing and was awarded through open competition with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order represents a...
- The Defense Logistics Agency awarded a delivery order valued at $2,074.80 to AmerisourceBergen Drug Corp for the supply of Emgality 120 mg/ml pen injectors. This competitive award, issued on August 14, 2025, with an ultimate completion date of August 15, 2025, represents a firm fixed price delivery order with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $3,116.22 to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Emgality 120 mg/ml in pen format. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under an open competition process. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 15, 2025. Emgality is a monoclonal antibody treatment...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $3,034.80 to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors. This firm fixed-price, competitively awarded contract was executed on August 4, 2025, with an ultimate completion date of August 5, 2025. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. No set-aside designation was applied to this award. This...
- The Defense Logistics Agency awarded a $3,458.00 firm fixed price delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injections on July 25, 2025, with an ultimate completion date of July 28, 2025. This non-set-aside award was competitively procured and will be performed at the contractor's corporate headquarters in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, supplied the product...
- The Defense Logistics Agency awarded a $1,729.00 firm fixed price delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors, with an ultimate completion date of July 25, 2025. This non-set-aside competitive award represents a single delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The product will be delivered to the contractor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a delivery order valued at $1,990.63 to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors, with an ultimate completion date of August 12, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, serves as the...
- The Defense Logistics Agency awarded a delivery order valued at $2,457.00 to AmerisourceBergen Drug Corp for the supply of Emgality 120 mg/ml pen injectors. This competitive, firm fixed-price delivery order was executed on August 25, 2025, with an ultimate completion date of August 26, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The contract represents a child order under AmerisourceBergen's larger Indefinite...
- SPE2DB25D3022Indefinite Delivery Contract
- SPE2DB25D3022-SPE2DB25FWCKXDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/ml prefilled pens with a ceiling value of $2,064.79 under a firm fixed price contract type. The award was made on September 2, 2025, with an ultimate completion date of September 3, 2025, and represents a non-competitive set-aside delivery against AmerisourceBergen's existing contract vehicle. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, AmerisourceBergen's corporate headquarters location. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a leading pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen serves as a critical vendor for federal medical procurement, supplying medications, vaccines, medical devices, and specialized healthcare commodities to military and veteran healthcare systems. Emgality is a migraine treatment medication, reflecting the company's portfolio that spans multiple therapeutic domains including neurological treatments, pain management, diabetes medications, and other specialized medical supplies to support military healthcare programs globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.1k | 9/2/25 |